BioEntrepreneurship - The Business of Biotech
COURSE DESCRIPTION
This session is designed to provide participants with an understanding of the process of drug and medical device development, starting with building new devices or identifying candidate drugs and taking these through the development process. Participants will discuss the risks inherent in bringing drugs and devices to market and the strategies that companies use to compete across the value chain to mitigate those risks.TOPICS ADDRESSED
- Overview of the Pharmaceutical and Biotechnology Market
- Needs and drivers of the biotechnology industry
- Current markets/disease indications
- New opportunities
- Economics and Risks of Drug Development
- Viable Business Models and Strategies
- Overview of business models
- Developing a commercial plan and effective strategy
- Case Study
- From academic scientist to successful entrepreneur (Ramon Felciano)
LEARNING OBJECTIVES
- Explore the development of regulated drugs and devices
- Understand where and how value is generated in the pharmaceuticals industry
- Appreciate the interplay between science and business in a biotech company
DATE | TIME | LOCATION
October 16, 2006 - October 16, 20066:00PM - 9:00PM
Collaboration Centre – CR-3
101 College St, Toronto
DOWNLOADS AND RESOURCES
- Presentation with audio - Dial-up connection (mp4)
- Presentation with audio - Broadband connection (mp4)
- Presentation with audio - podcast
- Event Blog and questions
ABOUT THE SPEAKERS
Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
Lynne is an experienced executive in the life science industry who has been involved in the launching and building of several successful companies. Her biotechnology experience spans all aspects of corporate development, operations and finance. With over 15 years of industry experience, she has played a key role in raising private capital, establishing operations, setting the overall corporate strategy, negotiating and integration of mergers/acquisitions, and establishing strategic alliances.
As the President and Managing Principal of Zydowsky Consultants, a consulting practice offering services to emerging companies, Dr. Zydowsky works with founders, investors and management teams to build the foundations of young life science companies.
Previously, Dr. Zydowsky was a cofounder of Renovis, Inc. She served as the initial President and COO and a member of the Board of Directors, and later as the COO and SVP of Business Development and SVP of Corporate Development. There she was responsible for all startup operations and corporate development. While at Renovis, she was part of the team which raised over $50 million in venture capital funding. She also played a key role in the evaluation and acquisition of assets of a drug development company. During her tenure Dr. Zydowsky helped recruit key members of the management and scientific staff and together with the executive team, was responsible for the growth of the company to over 70 employees which led to the initial public offering in February 2004.
Prior to Renovis, Dr. Zydowsky joined Exelixis, Inc. as its first employee and held various positions of increasing responsibility including VP of Pharmaceutical Business Development and VP of Corporate Technology Development. As a member of the senior management team, she was responsible for the growth and transition of the company to 150 employees which led to the initial public offering in April 2000. While at Exelixis, she worked to establish corporate operations, secured initial funding and initiated the Corporate Technology Development Department which is responsible for all licensing and enabling IP. In addition, she was responsible for pharmaceutical business development, participated in the corporate partnership negotiations and management of the company’s partnered agricultural and pharmaceutical alliances with Bayer, Pharmacia (now Pfizer) and Bristol-Myers Squibb.
Dr. Zydowsky earned her Ph.D. in chemistry from The Ohio State University and was a National Institutes of Health Postdoctoral Fellow in the Department of Biological Chemistry and Molecular Pharmacology at the Harvard Medical School. She was a Senior Research Scientist at Ariad Pharmaceuticals and Glaxo Research Institute (now GSK).
Dr. Ramon Felciano, CTO and Vice President of Research, Ingenuity Systems
In 1998 Dr. Felciano co-founded Ingenuity Systems and currently leads the company's R&D efforts as the Chief Technology Officer and Vice President of Research. Prior to Ingenuity, Dr. Felciano co-founded SUMMIT, the Stanford University Medical Media and Information Technologies lab, where he held the position of Associate Director for four years. SUMMIT is a research and development center dedicated to the exploration of new applications of computers in medical education and information exchange, and to the construction of a rich, computer-based learning environment for the medical student and practitioner. Dr. Felciano is the founder of Digital Alchemy, a design and consulting firm based in Palo Alto, California which specializes in user interface design and evaluation, and in specialized software solutions for health care and technology markets.
Dr. Felciano holds a Ph.D. and M.S. in Biomedical Informatics, a B.S. in Computer Science and a B.A. in English and French Literature from Stanford University. While at Stanford, he performed research on innovative methods for designing intelligent user interfaces, scientific information visualization, and distributed knowledge-based biomedical information systems. Dr.Felciano's doctoral research was performed in the laboratory of Professor Russ Altman and focused on the automatic generation of biomedical graphics and their use as the bases for biomedical user interfaces. Dr. Felciano is a founding member of the RiboWeb, a project to build a World Wide Web-based knowledge base to support to collaborative molecular biology over the Internet. His other research efforts include Lamprey, a patented user tracking technology for the World Wide Web; and the study of Human Error in Medicine and its impact on the design of medical information systems. Dr. Felciano has authored several patents, articles and papers in journals such as Nature, Gene, ISMB, Briefings in Bioinformatics, AMIA, CHI, and STQE.
ABOUT THE BIO-ENTREPRENEURSHIP SERIES
Click here for more information about the BioEntrepreneurship Series.UPCOMING EVENTS
PAST EVENTS
- March 12, 2008
BioEntrepreneurship: What Investors Look For in Life Science Businesses - February 27, 2008
BioEntrepreneurship: Budgeting for life science companies - February 6, 2008
BioEntrepreneurship: Life Science IP - January 16, 2008
BioEntrepreneurship: Navigating the Global Regulatory Path for New Drugs - January 9, 2008
BioEntrepreneurship: Market Assessement for Therapeutics and Medical Devices - December 19, 2007
BioEntrepreneurship: Business Models in Therapeutics and Medical Devices - June 12, 2007
BioEntrepreneurship - Effective Communications: Selling your story to VCs and beyond - May 14, 2007
BioEntrepreneurship - Strategic Financing of Biotech - April 16, 2007
BioEntrepreneurship - VCs and CVs: Managing the people/profit equation - February 12, 2007
BioEntrepreneurship - Clinical Trials Strategy - January 15, 2007
BioEntrepreneurship - Navigating the Global Regulatory Path for New Drugs - December 4, 2006
BioEntrepreneurship - Intellectual Property Strategy - November 13, 2006
BioEntrepreneurship - Market Assessment: Great New Product or Just Really Cool Science? - October 16, 2006
The Business of Biotech
MaRS PICKS
Who's Your City?
MaRS BLOG
- Fail to design = design to fail
- Experience is our obsession: Innovation and the design ecosystem
- Tech in the Soo